According to GlobalData’s medical device pipeline database, 27 Drugs of Abuse / Toxicology Rapid Tests devices are in various stages of development globally. GlobalData’s report Drugs of Abuse / Toxicology Rapid Tests provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, five are in active development, while the remaining 22 are in an inactive stage of development. There are three products in the early stages of development, and the remaining two are in the late stages of development.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Drugs of Abuse / Toxicology Rapid Tests pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Drugs of Abuse / Toxicology Rapid Tests devices. Overall, most of these Drugs of Abuse / Toxicology Rapid Tests pipeline devices are being developed by private entities.
Key players involved in the active development of Drugs of Abuse / Toxicology Rapid Tests include BioMedomics, American Bio Medica, Group K Diagnostics, I-calQ, ImmunoScience, Lumos Diagnostics, Ricovr Healthcare, Seacoast Science, Thermo Fisher Scientific and True Diagnostics.
For a complete picture of the developmental pipeline for Drugs of Abuse / Toxicology Rapid Tests devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.